

# **Teaser Memorandum**

MYCOPLUS CO. LTD.

Title(Name of Technology) :

Natural compound, MP1029, for cholesterol control

November 28, 2012



Executive Summary	IP Owner Summary
- 2000. 07. 06	MYCOPLUS Co., Ltd.
- Approximately 10 natural bioactive compounds are either being developed in the lab or are on the way of being patented. They are involved in antibiotics-resistant pathogens, oral and respiratory diseases, acne, inflammatory skin, dandruff, seborrheic dermatitis,	
atopic dermatitis, psoriasis, tineas, candidiasis and so on.	Personal Description of
- Mycoplus was established with the goals of developing natural medicinal candiates, healthy food ingredients and cosmeceutical products	Researcher
cholostoral control for modicing and healthy food ingradient	Name: Cheol-Sik Yoon
	Present Position:CEO
- natural compound with superiority at its efficacy	Major:Microbiology
Industry Sector: medicine and healthy food	<ul> <li>Research interest.: Bioactive compound derived from fungi</li> </ul>
Therapeutic Target: Cholesterol	<ul> <li>Office address: 201 Myung Seong</li> <li>Bldg., 996-2 Hogye-dong, Dongan-gu,</li> <li>Anyang, Gyeonggi-do, 431-080 Korea</li> </ul>
State of Development: early stage	Market Feasibility
	Domestic and foreign market size:
Key Technology Highlights	<ul> <li>Domestic and foreign market opportunity (competitors and competing product):</li> </ul>
□ MP1029-excreting fungus has been traditionally used in Korea as seed strain for oriental medicine production	
□ Shows moderate efficacy on reduction of cholestrol by inhibiting HMG-CoA reductase and squalane synthase	Trend & Partnership
□ No cytotoxicity observed	Future outlook and trends related to technology:
Proposal Abstract	<ul> <li>Technology Transfer and Commercialization conditions: We intend to enter into a technology transfer or licensing transaction with respect to our technologies including active ingredients and related bioprocess technology.</li> </ul>
	<ul> <li>Type of business relationship sought (including licensing availability):</li> </ul>
KHIDI	2



# Technology Overview Technology Platform - Natural compound with approx. m.w 290, derived from a fungal liquid fermentation. - MP1029-excreting fungus has been traditionally used in Korea as seed strain for oriental medicine production - Shows moderate efficacy on reduction of cholestrol by inhibiting HMG-CoA reductase and squalane synthase - No cytotoxicity observed Background and unmet needs Discovery and Achievements (Compound submission only) - Cholesterol control - Inhibition of squalane synthase - Moderate efficacy on reduction of cholesterol - LC50: 0.44uM - Animal test showed the same results as in vitro test - Any change at liver, body weight, and food consumption was not observed.



#### Toxicological data

	Body weight (g)	Relative liver weight	Average daily food consumption (g/day)
No treatment	286.3±4.1	3.1±0.32	20.2±1.0
Simvastatin(1mg/kg/day)	280.2±7.3	2.7±0.26	21.5±1.1
MP1029(1mg/kg/day)	286.0±9.2	3.0±0.25	20.8±1.0
MP1029(2.5mg/kg/day)	284.1±5.6	2.9±0.18	21.0±0.9
MP1029(5mg/kg/day)	280.9±2.5	2.9±0.17	20.4±0.7

### Patents and Publications

#### TABLE

Country	Patent, Publication or Appln. No.	Status	Description

## Contact Point

KHIDI (Korea Health Industry Development Institute) is currently receiving inquiries from interested parties in this transaction. If you are interested, please contact any of the KHIDI professionals below:

Name	Title	Tel. number	E-mail address